These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 38616994)

  • 21. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players.
    Zimmet P; Boyko EJ; Collier GR; de Courten M
    Ann N Y Acad Sci; 1999 Nov; 892():25-44. PubMed ID: 10842650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.
    Carr MC; Brunzell JD
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2601-7. PubMed ID: 15181030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: a systematic review.
    Cantiello F; Cicione A; Salonia A; Autorino R; De Nunzio C; Briganti A; Gandaglia G; Dell'Oglio P; Capogrosso P; Damiano R
    Int J Urol; 2015 Jan; 22(1):22-32. PubMed ID: 25345683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study.
    Onat A; Sari I; Hergenç G; Yazici M; Uyarel H; Can G; Sansoy V
    Metabolism; 2007 Mar; 56(3):348-56. PubMed ID: 17292723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
    Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
    Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.
    DeFronzo RA; Ferrannini E
    Diabetes Care; 1991 Mar; 14(3):173-94. PubMed ID: 2044434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus.
    Ginsberg HN; MacCallum PR
    J Cardiometab Syndr; 2009; 4(2):113-9. PubMed ID: 19614799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
    Kones R
    Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dyslipidemia and obesity 2011. Similarities and differences].
    Ceska R; Vrablík M; Sucharda P
    Vnitr Lek; 2011 Mar; 57(3):248-53. PubMed ID: 21495405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study.
    Onat A; Uyarel H; Hergenç G; Karabulut A; Albayrak S; Can G
    Atherosclerosis; 2007 Mar; 191(1):182-90. PubMed ID: 16678831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology and factor analysis of obesity, type II diabetes, hypertension, and dyslipidemia (syndrome X) on the Island of Kosrae, Federated States of Micronesia.
    Shmulewitz D; Auerbach SB; Lehner T; Blundell ML; Winick JD; Youngman LD; Skilling V; Heath SC; Ott J; Stoffel M; Breslow JL; Friedman JM
    Hum Hered; 2001; 51(1-2):8-19. PubMed ID: 11096265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.
    Zwirska-Korczala K; Konturek SJ; Sodowski M; Wylezol M; Kuka D; Sowa P; Adamczyk-Sowa M; Kukla M; Berdowska A; Rehfeld JF; Bielanski W; Brzozowski T
    J Physiol Pharmacol; 2007 Mar; 58 Suppl 1():13-35. PubMed ID: 17443025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes and metabolic syndrome (MS).
    Bellomo A; Mancinella M; Troisi G; Ettorre E; Marigliano V
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():61-7. PubMed ID: 17317435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rubrometabolic Syndrome.
    Kalra S; Coetzee A; Kalra PA; Saldaña JR; Kilov G
    Minerva Endocrinol (Torino); 2023 Mar; 48(1):59-75. PubMed ID: 33331741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathology of metabolically-related dyslipidemia.
    Su X; Chen X; Wang B
    Clin Chim Acta; 2021 Oct; 521():107-115. PubMed ID: 34192528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study.
    Purnell JQ; Zinman B; Brunzell JD;
    Circulation; 2013 Jan; 127(2):180-7. PubMed ID: 23212717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent research progress on the correlation between metabolic syndrome and
    Xie Q; He Y; Zhou D; Jiang Y; Deng Y; Li R
    PeerJ; 2023; 11():e15755. PubMed ID: 37483988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psoriasis and Metabolic Disorders: A Comprehensive Meta-Analysis of Million Adults Worldwide.
    Alajroush WA; Alrshid AI; Alajlan AH; Alsalamah YB; Alhumaidan MI; Alhoumedan AI; Alrasheed MI; Alowairdhi YA; Alowirdi F; Aljoufi AZ; Alsubaie DS; Alarfaj NH
    Cureus; 2024 Jan; 16(1):e52099. PubMed ID: 38344577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].
    Ruetsch O; Viala A; Bardou H; Martin P; Vacheron MN
    Encephale; 2005; 31(4 Pt 1):507-16. PubMed ID: 16389718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenetic pathways of cognitive dysfunction and dementia in metabolic syndrome.
    Borshchev YY; Uspensky YP; Galagudza MM
    Life Sci; 2019 Nov; 237():116932. PubMed ID: 31606384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.